Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7658)
All Articles published online
|
Publishing Process of This Article
|
Sep 6, 2018 (publication date) through Nov 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zhang ZF, Luo YJ, Lu Q, Dai SX, Sha WH. Conversion therapy and suitable timing for subsequent salvage surgery for initially unresectable hepatocellular carcinoma: What is new? World J Clin Cases 2018; 6(9): 259-273 [PMID: 30211206 DOI: 10.12998/wjcc.v6.i9.259] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v6/i9/259.htm |
| Number | Citing Articles |
| 1 |
Haowen Tang, Yinbiao Cao, Yiping Jian, Xuerui Li, Junfeng Li, Wenwen Zhang, Tao Wan, Zhe Liu, Wei Tang, Shichun Lu. Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review. BioScience Trends 2022; 16(2): 130 doi: 10.5582/bst.2022.01019
|
| 2 |
Lei Xu, Lin Chen, Wei Zhang. Neoadjuvant treatment strategies for hepatocellular carcinoma. World Journal of Gastrointestinal Surgery 2021; 13(12): 1550-1566 doi: 10.4240/wjgs.v13.i12.1550
|
| 3 |
Hai-Tao Zhao, Jian-Qiang Cai. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma. World Journal of Gastroenterology 2021; 27(47): 8069-8080 doi: 10.3748/wjg.v27.i47.8069
|
| 4 |
Huaiyuan Wang, Ge Zhang, Xiaobo Yang, Zhenhui Lu, Haitao Zhao. Lenvatinib plus immune checkpoint inhibitors or locoregional therapy in unresectable hepatocellular carcinoma: Lessons learned and moving forwards. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2023; 1878(1): 188841 doi: 10.1016/j.bbcan.2022.188841
|
| 5 |
Jiongliang Wang, Zhikai Zheng, Tianqing Wu, Wenxuan Li, Juncheng Wang, Yangxun Pan, Wei Peng, Dandan Hu, Jiajie Hou, Li Xu, Yaojun Zhang, Minshan Chen, Rongxin Zhang, Zhongguo Zhou. Hepatic Arterial Infusion Chemotherapy as a Timing Strategy for Conversion Surgery to Treat Hepatocellular Carcinoma: A Single-Center Real-World Study. Journal of Hepatocellular Carcinoma 2022; : 999 doi: 10.2147/JHC.S379326
|
| 6 |
Kensuke Yamamura, Toru Beppu. Conversion surgery for hepatocellular carcinoma after multidisciplinary treatment including lenvatinib. Hepatology Research 2021; 51(10): 1029 doi: 10.1111/hepr.13691
|
| 7 |
Giovanni Battista Levi Sandri. Portal Vein Thrombosis. 2021; : 157 doi: 10.1007/978-981-33-6538-4_11
|
| 8 |
Ming‐Da Wang, Xue‐Jun Xu, Ke‐Chun Wang, Yong‐Kang Diao, Jia‐Hao Xu, Li‐Hui Gu, Lan‐Qing Yao, Chao Li, Guo‐Yue Lv, Tian Yang. Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities. Cancer Science 2024; 115(7): 2159 doi: 10.1111/cas.16194
|
| 9 |
Hanwen Liu, Haowen Deng, Chihua Fang, Jian Yang, Nan Xiang. ASO Author Reflections: Laparoscopic Right Posterior Sectionectomy with Preservation of Subsegment Using Digital Intelligence Liver Surgery Technologies in Patients with HCC After Conversion Therapy. Annals of Surgical Oncology 2024; 31(9): 5655 doi: 10.1245/s10434-024-15612-2
|
| 10 |
Di Zhou, Yi Dian Yang, Long Yang Jin, Yong Yang, Shou Hua Wang, Qiang Cai, Wen Bin Guan, Fei Ma, Liqin Xiong. Near-Infrared Polymer Dots in the Portal-Hepatic Circulation Achieve Localization of Hepatic Carcinoma In Vivo. ACS Applied Bio Materials 2020; 3(9): 6177 doi: 10.1021/acsabm.0c00729
|
| 11 |
Binkui Li, Jiliang Qiu, Yun Zheng, Yunxing Shi, Ruhai Zou, Wei He, Yichuang Yuan, Yuanping Zhang, Chenwei Wang, Zhiyu Qiu, Kai Li, Chengrui Zhong, Yunfei Yuan. Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma. Annals of Surgery Open 2021; 2(2): e057 doi: 10.1097/AS9.0000000000000057
|
| 12 |
Kazuhisa Takeda, Yuji Tsurumaru, Yuji Yamamoto, Kentaro Araki, Yu Kogure, Koichi Mori, Kazuya Nakagawa, Tetsuya Shimizu, Goro Matsuda, Hitoshi Niino, Hitoshi Sekido, Satoshi Kobayashi, Manabu Morimoto, Chikara Kunisaki, Itaru Endo. Treatment of hepatocellular carcinoma with hepatic vein tumor thrombosis protruding into the inferior vena cava by conversion surgery following chemotherapy with regorafenib: a case report. Clinical Journal of Gastroenterology 2020; 13(3): 428 doi: 10.1007/s12328-019-01077-4
|
| 13 |
Song Chen, Zhiqiang Wu, Feng Shi, Qicong Mai, Liguang Wang, Fan Wang, Wenquan Zhuang, Xiaoming Chen, Huanwei Chen, Bo Xu, Jiaming Lai, Wenbo Guo. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study. Journal of Cancer Research and Clinical Oncology 2022; 148(8): 2115 doi: 10.1007/s00432-021-03767-4
|